U.S. patent application number 10/904960 was filed with the patent office on 2005-08-04 for devices, systems and methods for patient infusion.
This patent application is currently assigned to INSULET CORPORATION. Invention is credited to Flaherty, J. Christopher.
Application Number | 20050171512 10/904960 |
Document ID | / |
Family ID | 22869381 |
Filed Date | 2005-08-04 |
United States Patent
Application |
20050171512 |
Kind Code |
A1 |
Flaherty, J. Christopher |
August 4, 2005 |
DEVICES, SYSTEMS AND METHODS FOR PATIENT INFUSION
Abstract
A method for transcutaneously delivering fluid to a patient
including providing at least one disposable infusion pump, wherein
the pump includes a housing adapted to be mounted on a patient's
skin, a transcutaneous patient access tool for extending through
the housing and providing transcutaneous access to the patient, a
reservoir prefilled with a therapeutic fluid, a dispenser for
causing fluid from the reservoir to flow to the transcutaneous
patient access tool, a processor connected to the dispenser and
programmed to cause a flow of fluid from the reservoir to the
transcutaneous patient access tool based on flow instructions, and
a wireless receiver connected to the processor for receiving flow
instructions from a remote controller and for delivering the flow
instructions to the processor.
Inventors: |
Flaherty, J. Christopher;
(Topsfield, MA) |
Correspondence
Address: |
INSULET CORPORATION
9 Oak Park Drive
Bedford
MA
01730
US
|
Assignee: |
INSULET CORPORATION
9 Oak Park Drive
Bedford
MA
|
Family ID: |
22869381 |
Appl. No.: |
10/904960 |
Filed: |
December 7, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10904960 |
Dec 7, 2004 |
|
|
|
10695547 |
Oct 28, 2003 |
|
|
|
10695547 |
Oct 28, 2003 |
|
|
|
09943992 |
Aug 31, 2001 |
|
|
|
6740059 |
|
|
|
|
60231476 |
Sep 8, 2000 |
|
|
|
Current U.S.
Class: |
604/890.1 |
Current CPC
Class: |
A61M 2005/14268
20130101; A61M 2205/50 20130101; A61M 2205/6072 20130101; A61M
2205/35 20130101; A61M 2005/1403 20130101; A61M 5/16813 20130101;
A61M 2209/01 20130101; A61M 5/14248 20130101; A61M 2205/3569
20130101; A61M 2005/1405 20130101; A61M 37/00 20130101; A61M
5/16809 20130101 |
Class at
Publication: |
604/890.1 |
International
Class: |
A61K 009/22 |
Claims
What is claimed is:
1. A method for transcutaneously delivering fluid to a patient,
comprising the steps of: a) providing at least one disposable
infusion pump including, a housing adapted to be mounted on a
patient's skin, a transcutaneous patient access tool for extending
through the housing and providing transcutaneous access to the
patient, a reservoir prefilled with a therapeutic fluid, a
dispenser for causing fluid from the reservoir to flow to the
transcutaneous patient access tool, a processor connected to the
dispenser and programmed to operate the dispenser so that fluid
from the reservoir flows to the transcutaneous patient access tool
based on flow instructions, and a wireless receiver connected to
the processor for receiving flow instructions from a remote
controller and for delivering the flow instructions to the
processor; b) placing the disposable infusion pump on a patient's
skin; c) receiving flow instructions from a remote controller
through the wireless receiver of the infusion pump; and d)
delivering the flow instructions to the processor of the infusion
pump, so that the processor causes fluid from the reservoir to flow
to the transcutaneous patient access tool based on the flow
instructions.
2. A method according to claim 1, wherein the reservoir is
prefilled with a therapeutic fluid that comprises one of insulin,
antibiotics, nutritional fluids, total parenteral nutrition or TPN,
analgesics, morphine, hormones or hormonal drugs, gene therapy
drugs, anticoagulants, analgesics, cardiovascular medications, AZT
or chemotherapeutics.
3. A method according to claim 1, wherein the reservoir is
prefilled with a therapeutic fluid for treating one of diabetes,
cardiovascular disease, pain, chronic pain, cancer, AIDS,
neurological diseases, Alzheimer's Disease, ALS, Hepatitis,
Parkinson's Disease or spasticity.
4. A method according to claim 1, further comprising the step of
adapting the prefilled reservoir so that the reservoir is not
refillable.
5. A method according to claim 1, further comprising the step of
providing each of the infusion pumps with an identification
tag.
6. A method according to claim 5, further comprising the step of
providing each of the identification tags with information
regarding the therapeutic fluid contained in the prefilled
reservoir, and wherein the information includes amount, type,
concentration and an expiration date of the therapeutic fluid.
7. A method according to claim 6, wherein the identification tags
comprise barcode labels.
8. A method according to claim 1, further comprising the step of
providing the processor with memory containing information
regarding the therapeutic fluid contained in the prefilled
reservoir, and wherein the information includes amount, type,
concentration and an expiration date of the therapeutic fluid.
9. A method according to claim 1, further comprising the step of
providing a plurality of the infusion pumps in a single sterilized
package.
10. A method according to claim 1, further comprising the step of
providing the infusion pump with a non-replaceable power
supply.
11. A method according to claim 1, further comprising the steps of
providing the infusion pump with skin attachment adhesive, and
attaching the infusion pump to the skin of a patient using the skin
attachment adhesive prior to receiving the flow instructions.
12. A method according to claim 1, further comprising the step of
freeing the housings, of each of the disposable infusion pumps, of
user input components for supplying flow instructions to the
processor.
13. A method according to claim 12, further comprising the steps of
placing the infusion pump on the patient's skin and extending the
transcutaneous patient access tool from the housing such that the
transcutaneous patient access tool penetrates the patient's skin,
prior to receiving the flow instructions.
14. A method according to claim 13, further comprising providing
each of the disposable infusion pumps with means for automatically
deploying the transcutaneous patient access tool from the housing
and into the patient's skin.
15. A method according to claim 1, further comprising the step of
remotely supplying flow instructions to each of the disposable
infusion pumps through a reusable remote control device.
16. A method according to claim 15, further comprising the step of
adapting the reusable remote control device to be successively used
with the disposable infusion pumps.
17. A method according to claim 15, further comprising the step of
providing the reusable remote control device with a replaceable
power supply.
18. A method according to claim 15, further comprising the step of
packaging one of the remote control devices and a plurality of the
infusion pumps in a single sterilized package.
19. A method according to claim 15, further comprising the steps of
providing the remote control device with a glucometer and using the
glucometer to measure a level of sugar within the patient's
blood.
20. A method according to claim 16, further comprising the steps of
providing each disposable infusion pump with a barcode label
containing information regarding the therapeutic fluid contained in
the prefilled reservoir, providing the remote control device with a
barcode scanner, and reading each of the barcode labels using the
barcode scanner.
21. A disposable infusion pump comprising: a housing adapted to be
mounted on a patient's skin; a transcutaneous patient access tool
for extending through the housing and providing transcutaneous
access to the patient; a reservoir prefilled with a therapeutic
fluid; a dispenser for causing fluid from the reservoir to flow to
the transcutaneous patient access tool; a processor connected to
the dispenser and programmed to operate the dispenser so that fluid
from the reservoir flows to the transcutaneous patient access tool
based on flow instructions; and a wireless receiver connected to
the processor for receiving flow instructions from a remote
controller and for delivering the flow instructions to the
processor.
22. A disposable infusion pump according to claim 21, wherein the
reservoir is prefilled with a therapeutic fluid that comprises one
of insulin, antibiotics, nutritional fluids, total parenteral
nutrition or TPN, analgesics, morphine, hormones or hormonal drugs,
gene therapy drugs, anticoagulants, analgesics, cardiovascular
medications, AZT or chemotherapeutics.
23. A disposable infusion pump according to claim 21, wherein the
reservoir is prefilled with a therapeutic fluid for treating one of
diabetes, cardiovascular disease, pain, chronic pain, cancer, AIDS,
neurological diseases, Alzheimer's Disease, ALS, Hepatitis,
Parkinson's Disease or spasticity.
24. A disposable infusion pump according to claim 21, wherein the
prefilled reservoir is non-refillable.
25. A disposable infusion pump according to claim 21, further
comprising an identification tag.
26. A disposable infusion pump according to claim 25, wherein the
identification tag includes information regarding the therapeutic
fluid contained in the prefilled reservoir, and wherein the
information includes amount, type, concentration and an expiration
date of the therapeutic fluid.
27. A disposable infusion pump according to claim 26, wherein the
identification tag comprises a barcode label.
28. A disposable infusion pump according to claim 21, wherein the
processor includes memory containing information regarding the
therapeutic fluid contained in the prefilled reservoir, and wherein
the information includes amount, type, concentration and an
expiration date of the therapeutic fluid.
29. A disposable infusion pump according to claim 21, further
comprising a non-replaceable power supply contained in the housing
and connected to the processor.
30. A disposable infusion pump according to claim 21, further
comprising skin attachment adhesive on an exterior surface of the
housing.
31. A disposable infusion pump according to claim 21, wherein the
housing is free of user input components for supplying flow
instructions to the processor.
32. A disposable infusion pump according to claim 21, wherein the
transcutaneous patient access tool includes a sharpened tip for
penetrating the patient's skin, and the disposable infusion pump
includes means for automatically deploying the transcutaneous
patient access tool from the housing and into the patient's
skin.
33. A system including a disposable infusion pump according to
claim 21, and further comprising a reusable remote control device
for wirelessly providing flow instructions to the receiver of the
disposable infusion pump.
34. A system according to claim 33, comprising one of the reusable
remote control devices and a plurality of the disposable infusion
pumps.
35. A system according to claim 33, wherein the remote control
device includes a glucometer.
36. A method for distributing therapeutic fluids to patients,
comprising the steps of: a) providing disposable infusion pumps to
each patient, wherein the pumps each include, a housing adapted to
be mounted on a patient's skin, a transcutaneous patient access
tool for extending through the housing and providing transcutaneous
access for fluid to the patient, a reservoir prefilled with a
therapeutic fluid, a dispenser for causing fluid from the reservoir
to flow to the transcutaneous patient access tool, a processor
connected to the dispenser and programmed to operate the dispenser
so that fluid from the reservoir flows to the transcutaneous
patient access tool based on flow instructions, and a wireless
receiver connected to the processor for receiving flow instructions
from a remote control device and for delivering the flow
instructions to the processor, wherein each infusion pump is
adapted to be used only once for a predetermined period; and b)
providing a reusable remote control device to each patient, wherein
the remote control device is adapted to be used with only one of
the disposable infusion pumps at any one time, and wherein the
remote control device is adapted to provide flow instructions to
the wireless receiver of the disposable infusion pump.
37. A method according to claim 36, wherein the reservoirs of the
disposable infusion pumps are prefilled with a therapeutic fluid
that comprises one of insulin, antibiotics, nutritional fluids,
total parenteral nutrition or TPN, analgesics, morphine, hormones
or hormonal drugs, gene therapy drugs, anticoagulants, analgesics,
cardiovascular medications, AZT or chemotherapeutics.
38. A method according to claim 36, wherein the reservoirs of the
disposable infusion pumps are prefilled with a therapeutic fluid
for treating one of diabetes, cardiovascular disease, pain, chronic
pain, cancer, AIDS, neurological diseases, Alzheimer's Disease,
ALS, Hepatitis, Parkinson's Disease or spasticity.
39. A method according to claim 36, further comprising the step of
adapting the prefilled reservoirs of the disposable infusion pumps
so that the reservoirs are not refillable.
40. A method according to claim 36, further comprising the step of
providing each of the infusion pumps with an identification
tag.
41. A method according to claim 40, further comprising the step of
providing each of the identification tags with information
regarding the therapeutic fluid contained in the prefilled
reservoir, and wherein the information includes amount, type,
concentration and an expiration date of the therapeutic fluid.
42. A method according to claim 41, wherein the identification tags
comprise barcode labels.
43. A method according to claim 36, further comprising the step of
providing the processors of the disposable infusion pumps with
memory containing information regarding the therapeutic fluid
contained in the prefilled reservoirs, and wherein the information
includes amount, type, concentration and an expiration date of the
therapeutic fluid.
44. A method according to claim 36, further comprising the step of
providing a plurality of the infusion pumps in a single sterilized
package for distribution to patients.
45. A method according to claim 36, further comprising the step of
providing the infusion pumps with non-replaceable power
supplies.
46. A method according to claim 36, further comprising the steps of
providing the infusion pumps with skin attachment adhesive, so that
the infusion pumps can be attached and secured to the skin of a
patient using the skin attachment adhesive prior to receiving the
flow instructions from the remote control device.
47. A method according to claim 36, further comprising the step of
freeing the housings, of each of the disposable infusion pumps, of
user input components for supplying flow instructions to the
processor.
48. A method according to claim 47, further comprising the steps
of: providing the transcutaneous patient access tools of the
infusion pumps with sharpened distal ends for penetrating the
patient's skin; and extending the transcutaneous patient access
tool from the housing upon placing the infusion pumps on the
patient's skin so that the transcutaneous patient access tool
penetrates the patient's skin, prior to receiving the flow
instructions from the remote control device.
49. A method according to claim 48, further comprising the step of
providing each of the disposable infusion pumps with means for
automatically deploying the transcutaneous patient access tool from
the housing and into the patient's skin.
50. A method according to claim 36, further comprising the step of
providing the reusable remote control device with a replaceable
power supply.
51. A method according to claim 36, further comprising the step of
packaging one of the remote control devices and a plurality of the
infusion pumps in a single sterilized package for distribution to
new patients.
52. A method according to claim 36, further comprising the step of
providing the remote control device with a glucometer.
53. A method according to claim 36, further comprising the steps of
providing each disposable infusion pump with a barcode label
containing information regarding the therapeutic fluid contained in
the prefilled reservoirs, and providing the remote control device
with a barcode scanner.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a continuation of U.S. patent
application Ser. No. 10/695,547, filed Oct. 28, 2003, which is a
continuation of U.S. patent application Ser. No. 09/943,992, filed
Aug. 31, 2001, now U.S. Pat. No. 6,740,059, which claims priority
to provisional U.S. patent application Ser. No. 60/231,476, filed
on Sep. 8, 2000. All of these applications are assigned to the
assignee of the present application and incorporated herein by
reference.
FIELD OF THE DISCLOSURE
[0002] The present disclosure relates generally to medical devices,
systems and methods, and more particularly to small, low cost,
portable infusion devices and methods that are useable to achieve
precise, sophisticated, and programmable flow patterns for the
delivery of therapeutic liquids to a patient.
BACKGROUND OF THE DISCLOSURE
[0003] Today, there are many diseases and other physical ailments
that are treated by various medicines including pharmaceuticals,
nutritional formulas, biologically derived or active agents,
hormonal and gene based material and other substances in both solid
or liquid form. In the delivery of these medicines, it is often
desirable to bypass the digestive system of a patient to avoid
degradation of the active ingredients caused by the catalytic
enzymes in the digestive tract and liver. Delivery of a medicine
other than by way of the intestines is known as parenteral
delivery.
[0004] Parenteral delivery of various drugs in liquid form is often
desired to enhance the effect of the substance being delivered,
insuring that the unaltered medicine reaches its intended site at a
significant concentration. Also, undesired side effects associated
with other routes of delivery, such as systemic toxicity, can
potentially be avoided by parenteral delivery. Parenteral delivery
of liquid medicines may best be accomplished by infusing directly
into the cardiovascular system via veins or arteries, into the
subcutaneous tissue or directly into organs, tumors, cavities,
bones or other site specific locations within the body.
[0005] Parenteral delivery is often accomplished by administering
bolus injections using a needle and syringe, or continuously by
gravity driven dispensers or transdermal patch technologies. Bolus
injections often imperfectly match the clinical needs of the
patient, and usually require larger individual doses than are
desired at the specific time they are given. Continuous delivery of
medicine through gravity feed systems compromise the patient's
mobility and lifestyle, and limit the therapy to simplistic flow
rates and profiles. Transdermal patches have special requirements
of the medicine being delivered, particularly as it relates to the
molecular structure, and similar to gravity feed systems, the
control of the drug administration is severely limited.
[0006] Ambulatory infusion pumps have been developed for delivering
liquid medicaments to a patient. These infusion devices have the
ability to offer sophisticated fluid delivery profiles
accomplishing bolus requirements, continuous infusion and variable
flow rate delivery. These infusion capabilities usually result in
better efficacy of the drug and therapy and less toxicity to the
patient's system. An example of a use of an ambulatory infusion
pump is for the delivery of insulin for the treatment of diabetes
mellitus. These pumps can deliver insulin on a continuous basal
basis as well as a bolus basis.
[0007] The ambulatory pumps often work with a reservoir to contain
the liquid medicine, such as a cartridge or syringe, and use
electromechanical pumping or metering technology to deliver the
medication to the patient via tubing from the infusion device to a
needle that is inserted transcutaneously, or through the skin of
the patient. The devices allow control and programming via
electromechanical buttons or switches located on the housing of the
device, and accessed by the patient or clinician. The devices
include visual feedback via text or graphic screens, such as liquid
crystal displays (LCD), and may include alert or warning lights and
audio or vibration signals and alarms. The devices can be worn in a
harness or a pocket, or strapped to the body of the patient.
[0008] Currently available ambulatory infusion devices are
expensive, difficult to program and prepare for infusion, and tend
to be bulky, heavy and very fragile. Filling these devices or their
reservoirs can be difficult and require the patient to carry both
the intended medication as well as filling accessories when
traveling or even just going to work. The accuracy and safety
requirements of these devices are extremely important, based both
on the medicine being delivered and the condition of the patient.
Therefore, the devices require specialized care, maintenance and
cleaning to assure proper functionality and safety for their
intended long term use.
[0009] Clearly, therefore, there is a need for a programmable and
adjustable infusion system that is precise and reliable and can
offer clinicians and patients a small, low cost, light weight,
simple-to-use alternative for parenteral delivery of liquid
medicines.
SUMMARY OF THE DISCLOSURE
[0010] The applicant has determined that a sophisticated ambulatory
infusion device that can be programmed to reliably deliver variable
flow profiles of liquid medications, yet is small, light weight and
low cost, is needed. Smaller and lighter devices are easier to
carry and are more comfortable for the patient, even allowing the
device to be adhesively attached to the patient's skin similar to a
transdermal patch. An inexpensive device allows greater flexibility
in prescribing the device for use by reducing the financial burden
on healthcare insurance providers, hospitals and patient care
centers, as well as patients themselves. In addition, low cost
devices make more practical the maintenance of one or more
replacement devices. If the primary device is lost or becomes
dysfunctional, availability of the replacement avoids costly
expedited repair and down time.
[0011] Aspects of the present disclosure will enable cost
reductions significant enough to make the entire device disposable
in nature, being replaced as frequently as every two to five days.
A disposable device allows the medication to be prefilled by the
manufacturer and does not need the routine cleaning and maintenance
required by long term devices, greatly simplifying use for the
patient.
[0012] The present disclosure, therefore, provides a method for
transcutaneously delivering fluid to a patient, which includes
providing at least one disposable infusion pump. The disposable
infusion pump is provided with a housing adapted to be mounted on a
patient's skin, a transcutaneous patient access tool for extending
through the housing and providing transcutaneous access to the
patient, a reservoir prefilled with a therapeutic fluid, and a
dispenser for causing fluid from the reservoir to flow to the
transcutaneous patient access tool. The disposable infusion pump is
also provided with a processor connected to the dispenser and
programmed to cause a flow of fluid from the reservoir to the
transcutaneous patient access tool based on flow instructions, and
a wireless receiver connected to the processor for receiving flow
instructions from a remote controller and for delivering the flow
instructions to the processor.
[0013] The method further includes placing the disposable infusion
pump on a patient's skin, receiving flow instructions from a remote
controller through the wireless receiver of the infusion pump, and
delivering the flow instructions to the processor of the infusion
pump, so that the processor causes fluid from the reservoir to flow
to the transcutaneous patient access tool based on the flow
instructions.
[0014] According to one aspect of the present disclosure, the
methods also includes the step of remotely supplying flow
instructions to each of the disposable infusion pumps through a
reusable remote control device.
[0015] These aspects of the disclosure together with additional
features and advantages thereof may best be understood by reference
to the following detailed descriptions and examples taken in
connection with the accompanying illustrated drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] FIG. 1 is a sectional side view of a first exemplary
embodiment of a fluid delivery device in accordance with this
disclosure;
[0017] FIG. 2 is a perspective view of an exemplary embodiment of a
remote control device in accordance with this disclosure for use
with the fluid delivery device of FIG. 1;
[0018] FIG. 3 is a sectional side view of a second exemplary
embodiment of a fluid delivery device in accordance with this
disclosure;
[0019] FIG. 3a is an enlarged partial sectional view of a dispenser
for the device of FIG. 3, shown with an accumulator empty and ready
to be filled upon an inlet valve being opened;
[0020] FIG. 3b is an enlarged sectional view of the dispenser for
the device of FIG. 3, shown with the accumulator filled and ready
to dispense a pulse of fluid upon an outlet valve being opened;
[0021] FIG. 4 is a sectional side view of a third exemplary
embodiment of a fluid delivery device in accordance with this
disclosure;
[0022] FIG. 4a is an enlarged sectional side view of a reservoir
chamber of the device of FIG. 4;
[0023] FIG. 4b is an enlarged bottom plan view of a portion of the
reservoir chamber of the device of FIG. 4;
[0024] FIG. 5 is a sectional side view of a fourth exemplary
embodiment of a fluid delivery device in accordance with this
disclosure;
[0025] FIG. 5a is a bottom plan view of the device of FIG. 5;
[0026] FIG. 6 is a sectional side view of a fifth exemplary
embodiment of a fluid delivery device shown positioned on an outer
surface of skin and subcutaneous tissue of a patient;
[0027] FIG. 6a is a bottom plan view of the device of FIG. 6;
[0028] FIG. 7 is a sectional side view of a sixth exemplary
embodiment of a fluid delivery device in accordance with the
present disclosure;
[0029] FIG. 8 is a sectional side view of a seventh exemplary
embodiment of a fluid delivery device in accordance with the
present disclosure;
[0030] FIG. 8a is a top plan view of the device of FIG. 8;
[0031] FIG. 9 is a sectional side view of an eighth exemplary
embodiment of a fluid delivery device in accordance with the
present disclosure;
[0032] FIG. 9a is a perspective view of an infusion set compatible
with an outlet assembly of the device of FIG. 9;
[0033] FIG. 10 is a sectional side view of a ninth exemplary
embodiment of a fluid delivery device in accordance with the
present disclosure, with a mechanical stop button of the device
shown in the open position;
[0034] FIG. 10a is an enlarged sectional view of the stop button
assembly of the device of FIG. 10 with the button shown in the
closed position;
[0035] FIG. 11 is a sectional side view of a tenth exemplary
embodiment of a fluid delivery device in accordance with the
present disclosure;
[0036] FIG. 11a is an enlarged sectional view of a bolus button
assembly of the device of FIG. 11;
[0037] FIG. 12 is a perspective view of another exemplary
embodiment of a remote control device in accordance with the
present disclosure;
[0038] FIG. 12a is a sectional side view of the remote control
device of FIG. 12;
[0039] FIG. 13 is a top plan view of an eleventh exemplary
embodiment of a fluid delivery device in accordance with the
present disclosure;
[0040] FIG. 13a is a top plan view of a remote controller to be
combined with the fluid delivery device of FIG. 13 as part of a kit
in accordance with the present disclosure;
[0041] FIG. 13b is a top plan view of an insulin cartridge to be
combined with the fluid delivery device of FIG. 13 as part of a kit
in accordance with the present disclosure; and
[0042] FIG. 13c is a top plan view of a sterile infusion set to be
combined with the fluid delivery device of FIG. 13 as part of a kit
in accordance with the present disclosure.
[0043] Like reference characters designate identical or
corresponding components and units throughout the several
views.
DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS
[0044] Set forth hereinbelow are detailed descriptions of exemplary
embodiments of fluid delivery devices, systems and kits,
constructed in accordance with the present disclosure, as well as
methods for using the devices, systems and kits. The types of
liquids that can be delivered by the fluid delivery devices,
systems and kits of the present disclosure include, but are not
limited to, insulin, antibiotics, nutritional fluids, total
parenteral nutrition or TPN, analgesics, morphine, hormones or
hormonal drugs, gene therapy drugs, anticoagulants, analgesics,
cardiovascular medications, AZT or chemotherapeutics. The types of
medical conditions that the fluid delivery devices, systems and
kits of the present disclosure might be used to treat include
diabetes, cardiovascular disease, pain, chronic pain, cancer, AIDS,
neurological diseases, Alzheimer's Disease, ALS, Hepatitis,
Parkinson's Disease or spasticity.
[0045] In FIG. 1, there is illustrated, generally at 10, a fluid
delivery device according to the present disclosure. The device 10
generally includes an exit port assembly 70 adapted to connect to a
transcutaneous patient access tool, a dispenser 40 for causing
fluid from a reservoir 30 to flow to the exit port assembly, a
processor or electronic microcontroller (hereinafter referred to as
the "local" processor) 50 connected to the dispenser and programmed
to cause a flow of fluid to the exit port assembly based on flow
instructions from a separate, remote control device (an example of
which is shown in FIG. 2), and a wireless receiver 60 connected to
the local processor for receiving the flow instructions from the
separate, remote control device and delivering the flow
instructions to the local processor. The device also includes a
housing 20 containing the exit port assembly 70, the dispenser 40,
the local processor 50, and the wireless receiver 60. The housing
20 is free of user input components, such as external buttons
connected to the processor 50, for providing flow instructions to
the local processor 50 in order to reduce the size, complexity and
costs of the device 10, such that the device lends itself to being
small and disposable in nature.
[0046] In the exemplary embodiment of FIG. 1, the device 10 also
includes a reservoir 30 contained within the housing 20 and
connected to the dispenser 40. The reservoir 30 is provided with a
collapsible design such as a metal bellows or is made of a
collapsible material such as a silicone elastomer. The volume of
the reservoir 30 is chosen to best suit the therapeutic application
of the fluid delivery device 10 impacted by such factors as
available concentrations of medicinal fluids to be delivered,
acceptable times between refills or disposal of the fluid delivery
device 10, size constraints and other factors. For treatment of
Type I diabetics, for example, a reservoir of less than 5 ml, and
preferably 2 to 3 ml, is appropriate.
[0047] The local processor 50 contains all the computer programs
and electronic circuitry needed to allow a user to program the
desired flow patterns and adjust the program as necessary. Such
circuitry can include one or more microprocessors, digital and
analog integrated circuits, resistors, capacitors, transistors and
other semiconductors and other electronic components known to those
skilled in the art. The local processor 50 also includes
programming, electronic circuitry and memory to properly activate
the dispenser at the needed time intervals. In the exemplary
embodiment of FIG. 1, a power supply 80, such as a battery or
capacitor, is included and supplies power to the local processor
50.
[0048] When the local processor 50 activates the dispenser 40, a
specific amount of fluid exits the fluid delivery device 10 via the
exit port assembly 70. The exit port assembly 70 can include
elements to transcutaneously enter the patient, such as a needle or
soft cannula, or can be adapted to connect to a standard infusion
device that includes transcutaneous delivery means.
[0049] As shown, the housing 20 is free of user input components
for providing flow instructions to the local processor 50, such as
electromechanical switches or buttons on an outer surface 21 of the
housing, or interfaces otherwise accessible to a user to adjust the
programmed flow rate through the local processor 50. In order to
program, adjust the programming of, or otherwise communicate user
inputs to the local processor 50, the fluid delivery device 10
includes the wireless communication element, or receiver 60 for
receiving the user inputs from a separate, remote control device,
such as the separate, remote control device 100 of FIG. 2. Signals
can be sent via a communication element (not shown) of the remote
control device 100, which can include or be connected to an antenna
130, shown in FIG. 2 as being external to the device 100.
[0050] The remote control device 100 has user input components,
including an array of electromechanical switches, such as the
membrane keypad 120 shown. The control device 100 also includes
user output components, including a visual display, such as a
liquid crystal display (LCD) 110. Although not shown in FIG. 2, the
remote control device 100 has its own processor (hereinafter
referred to as the "remote" processor) connected to the membrane
keypad 120 and the LCD I10. The remote processor is programmed to
receive the user inputs from the membrane keypad 120 and translate
the user inputs into "flow" instructions for transmission to the
fluid delivery device 10, and is programmed to send user outputs to
the LCD I10.
[0051] A user, such as a patient or a clinician, can thus program
the fluid delivery device 10 by entering information into the
remote control device 100, which then downloads information to the
receiver 60 of the device 10 with each key stroke or button pressed
or in a batch mode of multiple key strokes. Complex flow
algorithms, requests for bolus delivery and other desired infusions
of the medicinal fluid can be accomplished by entering information
into the remote control device 100, which is then transmitted to
the fluid delivery device 10. The communication can be confirmed as
acceptable by the local processor 50 of the fluid delivery device
10 by using one or more features such as standard handshaking
protocols, redundant transmissions and other communication
confirmation methods, as are known to those skilled in the art.
[0052] The lack of user interfaces, such as electromechanical
switches on the fluid delivery device 10, results in substantial
reductions in the cost, the size, and the weight of the device 10.
The lack of user interfaces also allows the housing outer surface
21 of the device 10 to be relatively smooth, thereby simplifying
cleaning and preventing jewelry or clothing items such as sweaters
from catching on the device. Since the remote control device 100
also includes a visual display 110, the fluid delivery device 10
can be void of an information screen, further reducing cost, size
and weight. Lack of user interfaces, such as electromechanical
switches and information screens, greatly simplifies the design of
the fluid delivery device 10 and allows the device 10 to be made
more flexible and resistant to damage.
[0053] FIG. 3 shows another exemplary embodiment of the fluid
delivery device 10 of the present disclosure wherein the reservoir
30 is made of a flexible material and is enclosed in a reservoir
chamber 35, which can be defined by the housing 20 and housing
reservoir walls 27. The flexible reservoir 30 is placed in
compression by a compressing member 33 and compressing springs 34,
which are positioned between the compressing member 33 and the
housing 20. The compressed, flexible reservoir 30 causes fluid
inside the reservoir 30 to be at a pressure above atmospheric
pressure. In a preferred embodiment, a cross sectional area of the
compressing member 33 approximates a cross sectional area of the
reservoir 30.
[0054] Alternatively, the housing 20 may include a flexible
cantilever beam that contacts the reservoir 30 creating a pressure
within the reservoir 30 above atmospheric pressure. In another
alternative, the reservoir chamber 35 may be sealed and filled with
a gas, or a vapor-plus-fluid mixture, to place the fluid within the
reservoir 30 under pressure above atmospheric pressure. The gas can
be air, and the vapor-plus-fluid mixture can be Freon. The Freon
vapor-plus-fluid mixture provides the design advantage of near
constant pressure if the fluid delivery device 10 is maintained at
near constant temperature. In still another alternative embodiment,
the amount of gas placed in a sealed reservoir chamber 35 may be
chosen such that the reservoir 30 pressure is equal to or less than
atmospheric for the entire full to empty conditions of the
reservoir 30. If the fluid in the reservoir 30 is maintained at a
pressure equal to or below atmospheric, then the dispenser 40 is
provided in the form of a pump, such as a peristaltic drive pump,
for pumping fluid from the reservoir 30 to the outlet port assembly
70.
[0055] The reservoir 30 may be prefilled by the device manufacturer
or a cooperating drug manufacturer, or may include external filling
means consisting of a fill assembly 31. If the fluid delivery
device 10 is prefilled by the manufacturer, the local processor 50
can be provided with memory containing various information
regarding the prefilled drug including but not limited to, the type
or name and the concentration and volume of the fluid.
[0056] The fill assembly 31 can include a needle insertion septum
32. The reservoir 30 and other fluid path components may be placed
in a vacuum during the final manufacturing process to simplify
filling and priming of the fluid delivery device 10 for the
patient. Needle insertion septum 32 may be constructed of a
resealing elastomer such as silicone that allows a needle to
puncture septum to add fluid to the reservoir 30, yet reseal after
the needle is withdrawn. An alternative to the needle insertion
septum 32 is a standard fluid connection, such as a Luer connector,
which can be affixed to the fill assembly 31 in combination with a
one way valve such as a duck bill valve (not shown). The patient
could attach a syringe filled with the liquid medication to the
Luer connector and fill the fluid delivery device 10. The fill
assembly 31 may be designed so that the patient can fill the fluid
delivery device 10 one time only, such as by having the Luer
connection break off when the syringe is removed.
[0057] The dispenser 40 is connected in fluid communication with
the reservoir 30. When the device 10 is provided with a pressurized
reservoir 30, as shown in exemplary embodiment of FIG. 3, the
dispenser can include an inlet valve 41 connected to the reservoir,
and outlet valve 42 connected to the exit port assembly 70, and an
accumulator 43 connected between the inlet valve and the outlet
valve. Since the fluid in the reservoir 30 is maintained at a
pressure above atmospheric pressure, opening of the inlet valve 41
allows the accumulator to fill to the reservoir pressure, after
which the inlet valve is 41 is closed. At the proper time, as
determined by the local processor 50 programming and instructions
received from the remote control device, the outlet valve 42 can be
opened to dispense fluid to the exit port assembly 70, which is at
the pressure of the patient, or atmospheric pressure. The
accumulator 43 will then be at atmospheric pressure, and the outlet
valve 42 can be closed, ready for another repeat cycle.
[0058] The dispenser 40 of the exemplary embodiment of FIG. 3 does
not create a driving or pumping force on the fluid passing
therethrough, but rather acts as a metering device, allowing pulses
of fluid to pass from the pressurized reservoir 30, through the
dispenser 40, to the exit port assembly 70 at atmospheric pressure.
The inlet valve 41 and the outlet valve 42 of the dispenser 40 are
controlled by the local processor 50, which includes electronic
programming, controls and circuitry to allow sophisticated fluid
delivery programming and control of the dispenser 40.
[0059] FIG. 3a shows the dispenser 40 with the accumulator 43 at
atmospheric pressure. An accumulator membrane 44 is shown in its
non-distended state, caused by atmospheric pressure only. Inlet
valve 41 is closed, and outlet valve 42 may be open or closed, but
must have been opened since the last time inlet valve 41 was
opened. FIG. 3b shows the condition where outlet valve 42 is
closed, and inlet valve 41 has been opened. Because of the elevated
pressure of the fluid from the reservoir 30, the accumulator
membrane 44 is distended, thus increasing the volume of accumulator
43 by an accumulator volume 45. After the inlet valve 41 is closed,
the outlet valve 42 can be opened, to dispense the accumulator
volume 45 and allow the accumulator membrane 44 to retract to the
position shown in FIG. 3a.
[0060] The inlet valve 41 and the outlet valve 42 of the dispenser
40 and the local processor 50 are designed to prevent both valves
from being opened at the same time, precluding the reservoir 30 to
ever flow directly to the exit port assembly 70. The prevention of
both valves opening at the same time is critical and can be
accomplished via mechanical means, electrical means, or both. The
prevention can be accomplished in the dispenser 40 design, the
local processor 50 design, or both.
[0061] The dispenser 40 shown in FIGS. 3, 3a and 3b dispenses
finite pulses of fluid volume, called pulse volume (PV), with each
activation. The PV is determined by the properties, materials and
construction of the accumulator 43 and the accumulator membrane 44.
PV's delivered by infusion devices are typically chosen to be small
relative to what would be considered a clinically significant
volume. For insulin applications at a concentration of 100 units
per ml, a PV of less than 2 microliter, and typically 0.5
microliter, is appropriate. If the fluid delivery device 10 is
programmed via the remote control device 100 to deliver 2 units an
hour, the dispenser will deliver 40 pulses an hour, or a pulse
every 1.5 minutes. Such pulsitile flow is considered continuous if
the PV is small enough. Other drugs or concentrations may permit a
much larger PV. Various flow rates are achieved by adjusting the
time between pulses. To give a fixed volume or bolus, multiple
pulses are given in rapid succession until the bolus volume is
reached.
[0062] The PV may not always be constant enough to be within the
accuracy requirements of the fluid delivery device 10. One factor
impacting the PV is reservoir pressure. The fluid delivery device
10 may include means for monitoring reservoir pressure (RP) and
adjust the timing between pulses to achieve the desire flow
pattern. An example of such compensation would be to decrease time
between pulses as the PV decreases to maintain the programmed flow
rate. Means for monitoring such parameters as reservoir pressure RP
are described below. An alternative to monitoring reservoir
pressure is monitoring the volume of the reservoir 30. Each time a
pulse or series of pulses are delivered, a measurement of reservoir
volume can indicate whether a proper amount of fluid has been
delivered, both for individual pulses and cumulative pulses. The
system could also be designed to compensate fluid flow as errors
are detected. An example of a reservoir volume transducer means is
also described below.
[0063] The communication element 60 preferably receives electronic
communication from the remote control device 100 using radio
frequency or other wireless communication standards and protocols.
The information transferred includes codes or packets of codes that
the local processor 50 uses to confirm that the information was
received correctly, similar to the way standard telephone modem
communication is performed. More sophisticated codes can be
included to allow the information to be self-corrected or pinpoint
the area of bad information. In an even more preferred embodiment,
the communication element 60 is a two-way communication element,
including a receiver and a transmitter, for allowing the fluid
delivery device 10 to send information back to the remote control
device 100. In such an embodiment, the remote control device 100
also includes an integral communication element 60 comprising a
receiver and a transmitter, for allowing the remote control device
100 to receive the information sent by the fluid delivery device
10.
[0064] The power supply 80 can be integrated into the fluid
delivery device 10 and not accessible to a user. In an alternative
embodiment, however, the power supply 80 can be replaceable, e.g.,
a replaceable battery. In another embodiment, the power supply 80
can comprise an integrated battery or capacitor, for low power
components of the device 10 such as the electronic memory, and a
user-inserted battery for powering the remainder of the device 10.
Other components that may require electrical energy are the
communication element 60, the dispenser 40, and other components
such as sensors or transducers.
[0065] As shown in FIG. 3, the device can include sensors or
transducers such as a reservoir volume transducer 37. A similar
transducer is described in U.S. Pat. No. 5,533,389 to Kamen et al.
FIG. 3 also shows a pressure transducer 221, located on the housing
reservoir walls 27 and in contact with a portion of the reservoir
30. The pressure transducer 221 may consist of force sensing
resistor technology such as that manufactured by Interlink, Inc. of
Camarillo, Calif. Reservoir transducer 37 or pressure transducer
221 can transmit information to local processor 50 to indicate how
and when to activate the dispenser 40, or to indicate other
parameters determining flow, as well as conditions such as the
reservoir 30 being empty or leaking, or the dispensing of too much
or too little fluid from the reservoir, etc.
[0066] FIG. 4 shows another exemplary embodiment of the fluid
delivery device 10 including an elastic sock 36 for compressing the
reservoir 30 to a pressure above atmospheric pressure. The
reservoir sock 36, constructed of an elastic material, has a very
small unexpanded internal volume, no larger than the volume of
reservoir 30 in its empty state. The reservoir sock 36 expands to
support reservoir 30 when full, and elastically compresses until
reservoir 30 is fully empty. Alternatively, the elastic reservoir
30 can be provided with a very small internal volume when empty,
typically less than 100 microliters, and that expands during the
fill process, creating a pressure within the reservoir greater than
atmospheric pressure until the reservoir 30 is again empty, thereby
obviating the need for the reservoir sock 36. The fluid delivery
device 10 of FIG. 4 also includes a Luer connector 71 for attaching
a standard transcutaneous fluid delivery set to the exit port
assembly 70.
[0067] Since the fluid delivery device 10 may be worn close to or
even attached to the body of a mammalian patient, it may be desired
to prevent the temperature of the fluid in the reservoir 30 from
elevating toward the body temperature of the patient. In one
embodiment, the reservoir chamber 35 can be sealed and placed in a
vacuum, similar to construction of a thermos bottle. The internal
surface of the reservoir chamber 35 can be coated with reflective
material, also similar to a thermos bottle. Alternatively, the
chamber 35 can be filled with insulating material such as a low
thermal conductance foam, with sufficient cavity size to allow the
reservoir 30 to expand to a maximum fill capacity. Shown in FIGS.
4a and 4b are venting holes 38, placed through the housing 20 and
housing outer surface 21 in the area of reservoir chamber 35 on the
side of the device 10 away from the skin of the patient. The
venting holes 38 allow the reservoir chamber 35 to vent to ambient
temperature and thus help cool the reservoir 30.
[0068] FIG. 5 shows another exemplary embodiment of the fluid
delivery device 10 that includes a second reservoir 90 in fluid
communication with a second dispenser 91. The additional reservoir
90 can be filled during the manufacturing process or can include
filling means similar to the fill assembly 31. The additional
dispenser 91 may include a separate controller, or can be
controlled by the same local processor 50. The additional dispenser
91 connects distally to tubing lumen 74 extending between the main
dispenser 40 and the exit port assembly 70. Similar to the main
dispenser 40, the additional dispenser 91 is designed and
controlled to prevent free flow of fluid from the additional
reservoir 90 to the exit port assembly 70.
[0069] The second reservoir 90 may be filled with a drug different
from the drug in the main reservoir 30, a diluent of the drug in
the main reservoir 30 or any inert substance. The fluid from the
additional reservoir 90 may be administered to dilute the fluid
dispensed from the main reservoir 30, to provide more sophisticated
or additive therapies, or even to maintain patency of the
transcutaneous fluid path by flowing an inert substance at a more
frequent rate then the intended infusion of the fluid in the main
reservoir 30.
[0070] Referring also to FIG. 5a, the device also includes a
transcutaneous patient access tool comprising transcutaneous
micropenetrators 75 connected to the exit port assembly 70. The
transcutaneous micropenetrators 75 include a series of
micro-needles or other micropenetrators that allow fluid to
transcutaneously enter the body of the patient without standard
needles. Similar transcutaneous micropenetrators are shown, for
example, in U.S. Pat. No. 5,983,136 to Kamen et al.
[0071] The device 10 further includes an adhesive layer 201 on the
outer surface 21 of the housing 20 for securing the device 10
directly to the skin of a patient. The adhesive layer is preferably
provided in a continuous, oval shape encircling the exit port
assembly 70 in order to provide a protective seal around the
penetrated skin. The housing adhesive layer 201 can consist of
material such as that used in bandages or electro surgery return
pads such as those manufactured by the Valley Lab division of
Tyco/U.S. Surgical.
[0072] FIGS. 6 and 6a show another exemplary embodiment of the
fluid delivery device 10 including a housing 200 having a recessed
surface 29 for creating an air pocket between the fluid delivery
device 10 and the skin 210 of a patient. The device 10 also
includes a secondary adhesive layer 202 attached to the first
adhesive layer 201, which is attached to the bottom surface of the
housing 200 surrounding the recessed surface 29. The secondary
adhesive layer 202 allows the device 10 to be attached, removed and
attached again to a patient. When first attached, the secondary
adhesive layer 202 adheres to the skin 210. Upon removal of the
device 10, the secondary adhesive layer 202 can be removed from the
first adhesive layer 201, and the fluid delivery device 10 can then
be reattached to the skin 210 using the adhesive layer 201.
[0073] A needle connection tubing 73 terminating in a skin
penetrating cannula 72 is shown connected to the exit port assembly
70. The needle connection tubing 73 is flexible, allows various
placements and can be reinforced to prevent kinking. Reinforcement
can be accomplished through choice of materials and ratio of wall
thickness to inner diameter, or the tubing 73 can be reinforced
with an internal wire coil. The skin penetrating cannula 72 can be
a rigid member, such as a needle, or can be flexible. The skin
penetrating cannula 72 is inserted through the skin 210 prior to
attaching the fluid delivery device 10 to the skin 210 and may be
inserted using a needle insertion assistance mechanism. Such a
needle insertion assistance mechanism may be integrated into the
fluid delivery device 10, or can be supplied as a separate
mechanism. FIG. 6 shows the cannula 72 entering through the surface
of the skin 210 and entering subcutaneous tissue 211. Once the
fluid delivery device 10 is attached to the skin 210, the needle
connecting tube 73 remains relatively stable due to the direct
connection between the device 10 and the skin 210. This stability
helps prevent kinking of the tubing 73 and resultant occlusion,
which is common to other ambulatory devices.
[0074] FIG. 7 shows another exemplary embodiment of the fluid
delivery device 10 including sensors providing feedback to the
local processor 50, an electronic assembly for the various
electronic devices and an optional second power supply 83. The
sensors include a volume sensor 222, for example, provided in
proximity with the reservoir 30 and an occlusion sensor 220 in
proximity with the exit port tubing lumen 74.
[0075] The microcontroller 50 can include a microprocessor 51,
memory 52, an electronic clock oscillator 53, an analog-to-digital
converter 54 and a multiplexer 55. Also shown in FIG. 7 is the
optional secondary power source 83, attached by the user to a
battery connector 81 connected to the microcontroller 50. A battery
door 82 is removed for insertion of the battery 83 and then
reattached by sliding the door in direction D1 to the housing 20 of
the fluid delivery device 10. In a preferred embodiment, the power
supply 80 provides electrical power for memory retention and low
power electronics only, while the secondary power source 83
provides electrical power for higher consumption components of the
device 10, such as the dispenser 40. Both the power supply 80 and
the secondary power source 83 may be consumer batteries, such as
alkaline or nickel cadmium batteries, or other energy storage
devices such as a capacitor. Additionally, both the power supply 80
and the secondary power source 83 may be rechargeable power
sources.
[0076] FIG. 8 shows another exemplary embodiment of the fluid
delivery device 10 including an electronic module 300 including the
local processor 50 and other electronic devices in a modular
subassembly, which simplifies manufacture, provides protection from
water or other fluid damage, and provides shielding and protection
from electromagnetic interference and static discharge. Attached to
the electronic module 300 and connected to the communication
element 60 is an optional antenna 61 to enhance transmitting of
signals from the fluid delivery device 10 via the communication
element 60. Alternatively, antenna 61 may be integrated into
electronic module 300.
[0077] The device of FIG. 8 includes an alarm transducer 223, such
as a beeper or vibration device, which is also integrated into the
electronic module 300. The electronic module 300 is shown
encapsulated by an electronic module housing 301, which is a
portion of the housing 20. The electronic module housing 301 can
easily be made to be waterproof, potentially by encapsulating the
entire assembly in potting material, and can be protected with
shielding material or coating for the electronic module 300 to
resist electromagnetic interference and electrostatic discharge
without having to encapsulate the entire internal portion of the
fluid delivery device 10. Alternatively, the housing 20, in the
portion surrounding the electronic module 300 can be shielded or
made waterproof, potentially by using a gasket material. The
optional antenna 61, which can be included internal or external to
the shielding material, is shown as external. The electronic module
300 may include a microprocessor, logic circuitry, read only
memory, writeable memory, random access memory, analog to digital
conversion circuitry, a multiplexer, the power supply 80,
resistors, capacitors, semiconductor components, programmable gate
arrays, operational amplifiers and various other analog and digital
electronic components.
[0078] FIG. 8a shows a transparent window 22 included in the
housing 20 of the fluid delivery device 10 of FIG. 8, which allows
a user to visually inspect the reservoir 30. Also shown is an
information barcode 26, which has information that can be read by a
remote control device 100 provided with a barcode scanner.
Information on the barcode 26 can include amount, type and
concentration of drug contained in the reservoir, the device
manufacturer and serial number, and expiration dates, and various
other pieces of information relative to infusion of liquid
medicines into mammalian patients.
[0079] FIG. 9 shows another exemplary embodiment of the fluid
delivery device 10 which includes a housing 200 having flexible
hinged sections 23 that allow the fluid delivery device 10 to flex
during patient movement to prevent detachment and aid in patient
comfort. The hinged sections 23 run along the length of the housing
20 and allow the fluid delivery device 10 to have flex along each
axis of the hinged sections 23. Directions of the axes of the
hinged sections 23 can be varied to provide optimum flexibility for
various patient contours and areas of placement.
[0080] FIG. 9a shows a standard transcutaneous infusion set 400
consisting of a penetrating cannula 405, usually consisting of a
needle bent to ninety degrees, a flexible tubing 404 and a Luer
connector 401, which includes standard threads 402. The infusion
set 400 may also include means for attaching to the skin of a
patient, such as infusion set wings 403, which may have adhesive
pads on their bottom side, or may be simply taped to the skin. This
connection to the skin may not be necessary when used with fluid
delivery device 10 with recessed housing 200. Infusion set 400 can
be attached to fluid delivery device 10 by connecting the infusion
set Luer connector 401 to the Luer connector 71 of the exit port
assembly 70 of the device 10.
[0081] FIG. 10 shows another exemplary embodiment of the fluid
delivery device 10 including a means for stopping flow without
requiring use of the remote control device 100. In this embodiment,
the means comprises a "t-shaped" stop button 230 that protrudes
through the housing 20 and is maintained in a deactivated position
through the force of stop button spring 231 The spring 231 is
positioned between the stop button 230 and a portion 24 of the
housing 20. Under normal conditions, fluid exits the dispenser 40,
travels through the exit port tubing lumen 74 and exits the exit
port assembly 70 unencumbered by stop button 230. As is shown in
FIG. 10a, when stop button 230 is pressed such that it overcomes
the force of the stop button spring 231, the stop button 232
compresses the exit port tubing lumen 74 against a second portion
25 of the housing 20, until the exit port tubing lumen 74 is fully
occluded. In the embodiment shown, the stop button 230 protrudes
through the housing 20. Alternatively, the device can be
constructed such that, in the deactivated position, the stop button
230 is flush with the housing outer surface 21 to prevent undesired
occlusion of flow by inadvertent pressing of the stop button 230.
The button size and shape can be designed to accommodate an index
finger, or the point of a pen. In addition, additional features can
be added to have the button 230 latch and hold after being pressed
against the lumen 74. The latching feature can be reversible, or
can required removal and disposable of the fluid delivery device
10.
[0082] FIG. 11 shows another exemplary embodiment of the fluid
delivery device 10 including a means for delivering a fixed amount
of fluid without requiring use of the remote control device 100. In
certain circumstances, it may be desirable to administer a specific
volume or bolus of fluid on demand without the use of the remote
control device 100. Described here is an embodiment 10 wherein the
user can press a mechanical bolus button 180 to release the bolus
of the intended medicine.
[0083] As also shown in FIG. 11a, the bolus button 180 is t-shaped
and protrudes through the housing 20. The button 180 is maintained
in a deactivated position through the force of bolus button spring
181 positioned between the bolus button 180 and an internal portion
of the housing 20. The bolus button 180 is attached to a bolus
release finger 183 via a pivoting bolus lever 187. The bolus lever
187 has a pivot 182 attached to the housing 20, and moves the bolus
release finger 183 away from a bolus delivery tubing lumen 186 and
a bolus button stop 28 of the housing when the bolus button 180 is
depressed against the spring 181. The bolus delivery tubing 186 is
in fluid communication with the exit port tubing lumen 74 and,
thus, the exit port assembly 70. When bolus button 180 is not
pressed, the bias from bolus button spring 181 causes the bolus
release finger 183 to press against bolus delivery tubing lumen 186
which presses against the bolus button stop 28 to occlude the bolus
delivery tubing lumen 186.
[0084] In order to deliver a fixed amount of fluid when the bolus
button 180 is pressed, a bolus flow restrictor 184 and a bolus
volume accumulator 185 are provided in the bolus delivery tubing
186. The bolus flow restrictor 184 acts as a flow limiter to
prevent free flow of fluid from the reservoir 30, and creates a
minimum lock-out period between full bolus volumes. Assuming in
this particular embodiment that the reservoir 30 is maintained at a
pressure above atmospheric pressure, the flow rate of the flow
restrictor 184 is chosen to be much slower than the rate at which
the bolus volume should be delivered.
[0085] The bolus volume accumulator 185 expands with the inflow of
fluid from the flow restrictor 184 as long as the bolus release
finger 183 is occluding the bolus delivery tubing 186. The amount
of expansion of the bolus volume accumulator 185 equals the bolus
volume to be delivered. When the bolus button 180 is depressed, the
bolus volume of fluid maintained in the bolus volume accumulator
185 is dispensed through the bolus delivery tubing lumen 186 and
out of the exit port assembly 70.
[0086] The time to dispense the bolus dose should be short since
there are no downstream flow restrictors, and the user could be
instructed to hold the button down for a required time, not more
than a few seconds. Alternative designs could latch the bolus
button 180 for a specific amount of time only, as the button must
be released to prevent continued flow via the flow restrictor 184.
After the bolus button 180 is pressed, bolus volume accumulator 185
fluid is delivered until the pressure in bolus volume accumulator
185 reaches atmospheric pressure. Release of bolus button 180
causes the bolus lever 187 to rotate back, pivoting around bolus
pivot 182 until bolus release finger 183 is occluding bolus
delivery tubing lumen 186 by pressing it against housing button
stop 28. Bolus volume accumulator 185 again expands an amount equal
to the next bolus volume to be delivered as fluid from reservoir 30
passes through bolus flow restrictor 184 until the pressure in
bolus volume accumulator 185 equals the pressure in reservoir
30.
[0087] In FIGS. 11 and 11a, the bolus button 180 is shown
protruding through housing 20. Alternatively, in the deactivated
position, bolus button 180 may be flush with the housing outer
surface 21 to prevent undesired bolus delivery by inadvertent
pressing of bolus button 180. In addition, while the figure shows a
design that allows multiple depressions of the bolus button 180,
alternative designs can make the bolus button 180 activation a
one-time event, requiring the user to replace the fluid delivery
device 10 or locate the remote control device 100.
[0088] FIGS. 12 and 12a depict a exemplary embodiment of the remote
control device 100 of the present disclosure. The remote control
device 100 is a hand held device that includes a controller housing
102, on which is mounted a visual display 110, such as a liquid
crystal display or LCD. The visual display 110 can visually
indicate status of programming, amounts, timing, and other
parameters of medicinal fluid delivery. Other information can
include time of day, address book, to do lists, and calendar
information and potentially an entertainment interface such as a
computer game. Another use of the visual display 110 is to display
information received or to be sent to devices other than the fluid
delivery device 100, such as a glucometer used by diabetic patients
or other diagnostic device, especially those whose information is
related to the desired infusion rates and volumes to be delivered
by fluid delivery device 10. The remote control device 100 may have
a diagnostic device, such as a blood glucose monitor or glucometer,
or an implantable glucose sensor reader, integrated into it,
simplifying the requirements of the patient by not having to carry
and maintain two separate devices. Other diagnostic devices include
but are not limited to blood diagnostic devices,
electrocardiography devices and readers, electroencephalogram or
EEG devices and readers, blood pressure monitors and pulse oxymetry
devices. Alternative to full integration of the diagnostic device,
would be connection to the device via wireless or hardwired
communication means, to perform a transfer of information.
[0089] The visual display 110 can also include information such as
warning and alarm conditions based on the status of the fluid
delivery device 100. Elements such as indicator lights, buzzers,
and vibrational alarms may also be included in the remote control
device 100 as alternative or redundant means for communicating
information to the user.
[0090] The user can get information and adjust the programming of
the device by depressing various electromechanical switches also
mounted on controller housing 102. These switches may be joined in
a bank of switches and included in membrane keypad 120 as shown in
FIGS. 111 and 11a and as is common with hand held electronic
devices. It is preferred that the choice of electromechanical
switches of the membrane keypad 120 interface with the visual
display 110 in a menu driven fashion making reading information and
programming the device more user friendly for the user. In an
alternative embodiment, the visual display 110 and membrane keypad
120 can be combined into a single device such as a touch screen
display, also common to electronic devices. Combination of touch
screen displays, membrane keypads and singular switches may all be
integrated into the remote control device 100.
[0091] The remote control device 100 may include various
electromechanical jacks, which can accept electromechanical plugs
from various devices. Shown in the figure are three plugs, a bar
code reader 140, a glucometer port 150 and a computer port 170.
These ports can allow two way transfer of information to enhance
the capabilities of remote control device 100 and improve its user
friendliness. FIG. 12a shows a schematic cross section of the
remote control device 100. The membrane keypad 120 and visual
display 110 are attached to the controller electronics 105.
Depicted is glucometer port 150 attached to the controller
electronics 105. Bar code reader 140 and computer port 170 are also
attached to the controller electronics, not shown. The controller
electronics are mounted and soldered to the controller printed
circuit board 101 as is the controller communication element
160.
[0092] The controller communication element 160 is designed to
transmit signals, or information to the communication element 60 of
the fluid delivery device 10. The controller electronics 105 act as
a "translator" in translating user inputs received through the user
interfaces 120 into signals for transmission by the controller
communication element 160. In a preferred embodiment, both the
communication element 60 and the controller communication element
160 are two way communication assemblies allowing two way
communication between the remote control device 100 and fluid
delivery device 10. In order to send wireless information the
communication element 60 and the controller communication element
160 may include inductive wire loops or other transmitting antenna
means. Information can be sent using amplitude or frequency
modulation, and can be broadcast in the radio frequency, or RF
range. Standard information confirmation techniques such as
handshaking or checksum protocols can be used to insure accurate
information transfer. With two-way communication, when errors are
detected, the transfer can be repeated until acceptable, a similar
technique to that utilized with two way pager technology
commonplace today.
[0093] If the fluid delivery device 10 is prefilled prior to
patient use, the electronic memory of local processor 50 may
contain information regarding the fluid including but not limited
to type or name, concentration, amount, volume, additional drugs in
solution and any diluting agents. This information can be
transmitted from the fluid delivery device 10 via its communication
element 60, and uploaded into the remote control device 100 via its
controller communication element 160. Other information may be
factory installed into the fluid delivery device 10 including but
not limited to manufacturing date, expiration date, sterilization
date, therapy information such as defined flow profiles and even
patient or hospital information. This information can be uploaded
into the remote control device 100 as described above, and the
remote control device 100 may adjust its internal programming based
on the information received.
[0094] In a preferred embodiment, the electronic memory of the
fluid delivery device 10 includes the latest program of the remote
control device 100 available at the time of manufacture of the
fluid delivery device 10. Similarly, the electronic memory of the
remote control device 100 includes the latest program of the fluid
delivery device 10, available at the time of manufacture of the
remote control device 100. At the first communication between the
remote control device 100 and the fluid delivery device 10, a
program check is performed, and if a newer software version for
either device is available from the other device, and the existing
hardware is compatible, another feature which can be programmed
into both devices, the newer program is downloaded into memory and
used by the upgraded device. The embedded program may be contained
in read only memory, or ROM, while the downloaded program can be
written into electronically writeable memory. The automatic update
feature, available for each device to upgrade the other, is another
way to make sure the user has the best available product for
use.
[0095] Another advantageous feature associated with two way
communication is the addition of a proximity alarm. The design of
the fluid delivery device 10 and remote control device 100
electronics can be such that when the distance between the two
devices is greater than a particular radial length, one or both of
the devices will alert the user, potentially with an audio alarm.
The alarming distance should be chosen so that it is less than the
maximum communication range of the two devices. A method of
creating the alarm is for the fluid delivery device 10 to send out
frequent packets of information at a predetermined rate and at an
amplitude or power less than the normal communication power,
providing a safety margin for the proximity detection. The remote
control device 100 is programmed to expect to receive this
communication at the predetermined rate, and lack of receipt of one
or more of these packets, causes the remote control device 100 to
activate its audio alarm 106. Alternatively or additionally, a
vibrational alarm may be included. Proximity alarms may be included
that do not require two way communication, by integrating a device
such as a magnet into the housing 20 of fluid delivery device 10,
and integrating magnetic field detection means into the remote
control device 100. When the magnetic field detection means of the
remote control device 100 do not detect the presence of the
magnetic field of the fluid delivery device 10, the remote control
device 100 activates the controller audio alarm 106.
[0096] The remote control device 100 includes a controller power
supply 108 that powers the various electronic components including
the controller electronics 105, controller audio alarm 106. The
controller power supply 108 may be a standard battery and in the
preferred embodiment, the power supply 108 may be replaceable by
the user by removing a battery door, not shown, and replacing after
power supply 108 is inserted and attached. In an alternative
embodiment, the power supply is integrated into the remote control
device 100, and can be recharged with a separate device or contains
enough power to supply the device for its intended length of
use.
[0097] The fluid delivery device 10 of the present disclosure may
be sold to hospitals, pharmacies, outpatient centers or the
patients themselves. If the fluid delivery device is intended for
short term or disposable use, it may be practical to sell each
device with various accessories or groups of accessories that are
convenient for the user. It may be desirable for certain parts of
the fluid delivery device, or accessories such as an attachable
transcutaneous infusion set, such as that described hereinabove, to
be packaged sterilized in a protective packaging. Proper aseptic
maintenance of the portion of the skin that receives the
transcutaneous access is important to prevent infection. FIGS. 13,
13a, 13b and 13c depict various components that may be packaged
together in kit form.
[0098] FIG. 13 shows the fluid delivery device of the present
disclosure including means for viewing the status of the reservoir
30 and an information barcode 26 with a sterilized device in a
sterile assembly pack 350. The device may be packaged separately or
with various other kit components. The fluid delivery device may be
packaged sterile entirely in a device pouch 351, intended to allow
sterilization and maintain sterility. Such pouches often are
constructed of materials such as TYVEK, a product of Dupont. The
sterile assembly pack 350 consists of the fluid delivery device 10
of the present disclosure, sealed in the device pouch 351 as is
shown in FIG. 13. Alternatively, a portion of the fluid delivery
device surrounding the exit port assembly 70 may be covered, sealed
and sterilized with a sterility maintaining covering (not
shown).
[0099] The top of the housing 20, or housing top side 203 includes
a housing transparent window 22 located above the reservoir 30. The
transparency of the housing transparent window 22 and design of the
reservoir 30 are such that the patient can determine information
regarding status of the reservoir 30 by viewing through the housing
transparent window 22. Such information can include amount of drug
remaining or presence of a leak. Alternatively, the entire housing
20 may be transparent yielding similar visual indications.
[0100] Also included in the fluid delivery device 10 of this
embodiment is an information barcode 26 which can include various
pieces of information regarding the status of that particular fluid
delivery device 10 such as type, volume and concentration of drug
prefilled in the device, expiration date of device or drug,
manufacture date of device or drug, serial numbers, lot numbers,
hospital name, clinician name, patient name, prescription
requirements and various other pieces of information. The barcode
information can be read into a hospital or home computer, or in the
preferred embodiment is uploaded via a barcode reader integral to
the remote control device 100. The fluid delivery device 10 and
remote control device 100 electronics and programming can be
designed such that the bar code must be read prior to programming
or otherwise using the fluid delivery device 10. This feature can
greatly reduce programming errors such as those associated with the
patient entering drug information. If the patient were to enter a
drug concentration that was incorrect, and did all the remaining
programming in units of drug, instead of volume, which is common
practice, while the device would function properly, all of the
volumes delivered would be inaccurate based on the ratio of the
incorrect concentration entered versus the true concentration of
the drug being delivered. Many drugs are available in multiple
concentrations such as insulin often made available to patients in
40, 50 and 100 units per ml concentrations.
[0101] FIG. 13a shows the remote control device 100 of the present
disclosure that could be packaged or provided as a kit with one or
more of sterile package assembly 350, including at least one fluid
delivery device 10. There is no need for the remote control device
100 to be sterilized, so if the fluid delivery device 10 was
sterilized, one or more sterile package assembly 350 can be boxed
or otherwise packaged with a single remote control device 100 along
with one or more other devices 10.
[0102] FIG. 13b shows a therapeutic fluid supply 250, which may
consist of a vial of drug such as insulin. The drug, in one or more
vials, which has been sterilized and made otherwise biocompatible
for use, can be packaged with one or more sterile package
assemblies 350 as well as with one or more remote control devices
100. Additional devices may be included in the kit if desired.
[0103] FIG. 13c shows a sterile infusion set assembly 407 including
the transcutaneous infusion set 400 described hereinabove packaged
in an infusion set pouch 406. The infusion set 400 includes an
infusion set Luer 401 connected to infusion set flexible tubing 404
and terminating in an infusion set penetrating cannula 405. An
optional set of infusion set wings 403 can be included to attach
the infusion set 400 to the patient's skin. In the preferred
embodiment of fluid delivery device 100, the transcutaneous
delivery means are integrated into exit port assembly 70, however
in an alternative embodiment, the exit port assembly 70 can be
attached to infusion set 400. In this particular embodiment, it may
be desirable to kit sterile infusion set assemblies 407 with any
quantity of one or more of the sterile assembly packs 350, the
fluid delivery device 10, the remote control device 100 or the
therapeutic fluid supply 250.
[0104] The fluid delivery device 10 of the present disclosure is
intended to be low cost and potentially disposable. It may be
advantageous for one or more of the components to be biodegradable,
since replacement of the device every two to five days has many
advantages, it would also generate a fair amount of waste. The
fluid delivery device 10 may include a preinstalled battery as its
power supply 80. In order to prevent the battery from powering the
electronics of fluid delivery device 10 before its intended use, a
mechanical switch may be included, connecting the battery contacts
to the electronics prior to programming with the remote control
device 100. A simplistic version of the switch design may be an
insulating material between the battery contacts of power supply 80
and the electrical connection to the local processor 50. The
insulating material could be designed to protrude through housing
20, and be removable by the user, not shown. The user could pull
the insulating material and remove it, simultaneously connecting
the battery contacts with the electrical connection to the local
processor.
[0105] The fluid delivery device 10 of the present disclosure may
be filled with the therapeutic fluid by the device manufacture, a
pharmaceutical company, or another manufacturer prior to its
shipment to the hospital, pharmacy or patient. Certain drugs
require refrigeration or other special environmental conditions,
requiring the prefilled fluid delivery device to be refrigerated or
otherwise handled to meet special requirements. Insulin is a drug
that requires refrigeration if it is to be stored for a prolonged
period of time. Hoechst, of Frankfurt Germany, is developing
insulin that is stable at higher temperatures. Drugs that are
stable at room temperature, such as the developmental insulin of
Hoechst, allow simple filling and handling of the fluid delivery
device 10, greatly simplifying the requirements for the
patient.
[0106] Various methods of using the fluid delivery device 10 are
included in the present disclosure and described above. The method
of programming the fluid delivery device 10 with remote programmer
100 as well as the attachment and use of the peripheral devices
including transcutaneous infusion sets and diagnostic devices such
as glucometers are described. Also relevant is the ability to
update the internal programming of either the fluid delivery device
10 or the remote control device 100 by the corresponding device.
Methods of filling the fluid delivery device 10 with therapeutic
fluid during the manufacturing process as well as by the user have
been described. Methods and timing of sterilization and packaging
of part or all of the fluid delivery device 10 and therapeutic
fluid have also been described.
[0107] Although exemplary embodiments of the disclosure have been
shown and described, many changes, modifications and substitutions
may be made by those having ordinary skill in the art without
necessarily departing from the spirit and scope of this disclosure.
For example, the fluid delivery device of this disclosure is
intended to be low cost, light weight, simple to use and
potentially disposable by removing a majority of the user
interface, including electromechanical switches, from the fluid
delivery device, and including a separate controller to replace
those functions. A reservoir, fluid dispenser, transcutaneous fluid
administration means, solid state electronics and wireless
communications are included in the fluid delivery device to perform
its intended function. While various means for reservoir
construction, pressurization means, fluid pumping means, fluid
metering means, transcutaneous delivery, electronic control and
wireless communications have been discussed in this application,
alternatives to each of these areas can be made without departing
from the spirit of the disclosure.
[0108] In addition, where this patent application has listed the
steps of a method or procedure in a specific order, it may be
possible (or even expedient in certain circumstances) to change the
order in which some steps are performed, and it is intended that
the particular steps of the method or procedure claims set forth
hereinbelow not be construed as being order-specific unless such
order specificity is expressly stated in the claim.
* * * * *